Skip to main content

Embracing Direct-to-Consumer Advertising by Focusing on Stopping Medications



There are plenty of examples of direct-to-consumer advertising that the pharmaceutical industry use to lure new customers. Just like the Cancer Center ads we discussed in the last GeriPal post, these ads almost universally do this by making emotional appeals to the consumer, as well as focusing on the benefits rather than presenting any real discussion of risks.

What if someone used a similar concept, but instead of trying to get people to take a drug, they try to convince patients to stop one. That’s just what Cara Tannenbaum and colleagues did in a paper published in JAMA IM, albeit they called it direct-to-consumer patient education and empowerment.

The Study

In brief, the authors of this study conducted a cluster randomized trial in Quebec in which a total of 303 long-term users of benzodiazepine medication aged 65-95 years were recruited from 30 community pharmacies. These pharmacies were randomized to either a control arm or the educational intervention arm.

The educational intervention was an eight page booklet that was mailed to the patient (and can be downloaded here) describing the risks of benzodiazepine use and a stepwise tapering protocol. Like other direct-to-consumer advertising, they also include a patient testimonial "intended to augment self-efficacy."

What they found was striking. Complete cessation of benzodiazepine use in the 6 months following randomization was achieved in 40 of the 148 (27%) in the intervention arm compared to 7 of the 155 (5%) in the control arm. Even better, the number needed to treat for any discontinuation or dose reduction was 3.7 in an intention to treat analyses.

The Take Away

Health care professionals should embrace direct to consumer advertising as it isn't going away.  How?  Just imagine a world (or just the US and New Zealand as I think they are the only Western nations that allow direct-to-consumer advertising) where after every time a drug company markets a drug to consumers, especially a potentially habit forming drug like the ad below, these companies also have to pay for an intervention like this one that gets those very same people off of their drug when it is no longer indicated or inappropriately prescribed.  Now that would make me sleep more comfortably at night.



by: Eric Widera (@ewidera)

Comments

Popular posts from this blog

Geroscience and it's Impact on the Human Healthspan: A podcast with John Newman

Ok, I'll admit it. When I hear the phrase "the biology of aging" I'm mentally preparing myself to only understand about 5% of what the presenter is going to talk about (that's on a good day).  While I have words like telomeres, sirtuins, or senolytics memorized for the boards, I've never been able to see how this applies to my clinical practice as it always feels so theoretical.  Well, today that changed for me thanks to our podcast interview with John Newman, a "geroscientist" and geriatrician here at UCSF and at the Buck Institute for Research on Aging.

In this podcast, John breaks down what geroscience is and how it impacts how we think about many age-related conditions and diseases. For example, rather than thinking about multimorbidity as the random collection of multiple different clinical problems, we can see it as an expression of the fundamental mechanisms of aging. This means, that rather than treating individuals diseases, targeting …

The Dangers of Fleet Enemas

The dangers of oral sodium phosphate preparations are fairly well known in the medical community. In 2006 the FDA issued it’s first warning that patients taking oral sodium phosphate preparations are at risk for potential for acute kidney injury. Two years later, over-the-counter preparations of these drugs were voluntarily withdrawn by the manufacturers.  Those agents still available by prescription were given black box warnings mainly due to acute phosphate nephropathy that can result in renal failure, especially in older adults. Despite all this talk of oral preparations, little was mentioned about a sodium phosphate preparation that is still available over-the-counter – the Fleet enema.

Why Oral Sodium Phosphate Preparations Are Dangerous 

Before we go into the risks of Fleet enemas, lets spend just a couple sentences on why oral sodium phosphate preparations carry significant risks. First, oral sodium phosphate preparations can cause significant fluid shifts within the colon …

Length of Stay in Nursing Homes at the End of Life

One out of every four of us will die while residing in a nursing home. For most of us, that stay in a nursing home will be brief, although this may depend upon social and demographic variables like our gender, net worth, and marital status. These are the conclusions of an important new study published in JAGS by Kelly and colleagues (many of whom are geripal contributors, including Alex Smith and Ken Covinsky).

The study authors used data from the Health and Retirement Study (HRS) to describe the lengths of stay of older adults who resided in nursing homes at the end of life. What they found was that out of the 8,433 study participants who died between 1992 and 2006, 27.3% of resided in a nursing home prior to their death. Most of these patients (70%) actually died in the nursing home without being transferred to another setting like a hospital.

 The length of stay data were striking:

the median length of stay in a nursing home before death was 5 months the average length of stay was l…